Literature DB >> 6944530

Natural cytotoxicity of peripheral blood lymphocytes and regional lymph node cells in breast cancer in women.

S Cunningham-Rundles, D A Filippa, D W Braun, P Antonelli, H Ashikari.   

Abstract

Natural cytotoxicity was studied before surgery or other treatment in 83 women with primary, untreated breast cancer. Peripheral blood lymphocytes (PBL) and cytotoxicity of regional lymph node cell(s) (RLNC) were examined in a 4-hour 51Cr release assay against the target cell K-562. Results indicated that greater than one-third of breast cancer patients have more negative lymphocyte cytotoxic activity toward K-562 than do the other two-thirds. Similar results were observed for PBL of 25 patients found to have benign breast lesions. Of these patients, 23 had fibrocystic disease. The difference between these findings and findings with normal control lymphocytes studied in parallel was highly significant (P less than 0.001). The study of RLNC cytotoxicity in patients with breast cancer showed that 25% of the patients' RLNC had significant natural cytotoxic activity toward K-562. Incubation of RLNC with interferon in vitro before addition of labeled K-562 cells did not induce cytotoxicity in RLNC that did not have this activity initially.

Entities:  

Mesh:

Year:  1981        PMID: 6944530

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  30 in total

1.  Long-term influence of adjuvant therapy on natural killer cell activity in breast cancer.

Authors:  E Tichatschek; C C Zielinski; C Müller; P Sevelda; E Kubista; K Czerwenka; J Spona; H Wolf; M M Eibl
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

2.  Modulation of natural killer cell activity in stage I postmenopausal breast cancer patients on low-dose aminoglutethimide.

Authors:  J Berry; B J Green; D S Matheson
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

Review 3.  The biology of the human natural killer cell.

Authors:  J C Roder; H F Pross
Journal:  J Clin Immunol       Date:  1982-10       Impact factor: 8.317

4.  Variation in natural killer activity in peripheral blood during the menstrual cycle.

Authors:  A N Sulke; D B Jones; P J Wood
Journal:  Br Med J (Clin Res Ed)       Date:  1985-03-23

5.  Serum suppression of lymphocyte activation in vitro in acquired immunodeficiency disease.

Authors:  S Cunningham-Rundles; M A Michelis; H Masur
Journal:  J Clin Immunol       Date:  1983-04       Impact factor: 8.317

6.  Effect on natural killer and antibody-dependent cellular cytotoxicity of adjuvant cytotoxic chemotherapy including melphalan in breast cancer.

Authors:  I R Mackay; M D Goodyear; C Riglar; J Penschow
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

7.  Kaposi's sarcoma. Gastrointestinal involvement correlation with skin findings and immunologic function.

Authors:  R K Saltz; R C Kurtz; C J Lightdale; P Myskowski; S Cunningham-Rundles; C Urmacher; B Safai
Journal:  Dig Dis Sci       Date:  1984-09       Impact factor: 3.199

Review 8.  Activation of lymphocyte anti-tumour responses in man: effector heterogeneity and the search for immunomodulators.

Authors:  B M Vose
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

9.  Native and inducible levels of natural cytotoxicity in lymph nodes draining mammary carcinoma.

Authors:  I Kimber; M Moore; A Howell; M J Wilkinson
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

10.  In vivo modulation of natural killer cell activity by tamoxifen in patients with bilateral primary breast cancer.

Authors:  E Robinson; D Rubin; T Mekori; R Segal; S Pollack
Journal:  Cancer Immunol Immunother       Date:  1993-08       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.